HCPLive Network

Role of Omega-3 in Secondary Prevention of CVD Questioned

Thursday, April 12 (HealthDay News) -- Sang Mi Kwak, M.D., from the Center for Cancer Prevention and Detection in Ilsan, South Korea, and colleagues conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the efficacy of eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of CVD. The final analyses included 14 trials involving 20,485 patients with a history of CVD.

The researchers found that consuming omega-3 fatty acid supplements was not associated with a significantly reduced risk of overall cardiovascular events (relative risk [RR], 0.99), or with all-cause mortality, sudden cardiac death, myocardial infarction, congestive heart failure, or transient ischemic attack and stroke. The slight reduction in cardiovascular death (RR, 0.91) did not persist when a methodologically flawed study was excluded from the analyses. No significant preventive effect was seen in any of the subgroups analyzed.

"Our meta-analysis showed insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease," the authors write.

The majority of the trials included in the study were funded by pharmaceutical companies.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

For patients with a history of cardiovascular disease, evidence is lacking for a secondary preventive effect of omega-3 fatty acid supplements, according to a meta-analysis published online April 9 in the Archives of Internal Medicine.

Copyright © 2012 HealthDay. All rights reserved.

Further Reading
Daily low-dose aspirin treatment may reduce global cognitive decline in older women at high risk for cardiovascular disease, according to a study published online Oct. 3 in BMJ Open.
Aortic arch pulse wave velocity (PWV), a measure of arterial stiffness, is a strong, independent predictor of future cerebrovascular disease.
The role of artificial sweeteners is potentially problematic, with consumption of artificially sweetened beverages (ASBs) associated with increased risks of cardiometabolic diseases.
Adults with cerebral palsy may be able to reduce declines in muscle strength, improve function, and reduce cardiovascular and metabolic disease by avoiding sedentary behavior and engaging in physical activity, according to a study published online Oct. 23 in Obesity Reviews.
The American Heart Association recently released the 2011 update to its cardiovascular disease prevention guidelines for women.
Stroke and subclinical markers of macrovascular disease are associated with cognitive decline in older adults with type 2 diabetes.
For patients with acute ST-segment elevation myocardial infarction, percutaneous coronary intervention (PCI) in non-infarct coronary arteries with major stenoses (preventive PCI) is associated with reduced subsequent cardiovascular risk, according to a study published online Sept. 1 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 31 to Sept. 4 in Amsterdam.
More Reading